RRML - Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- November 2024 -
 
Towards appropriate training f... 31
Recomandările naționale ale ... 28
Biomarkers of acute kidney inj... 23
A comprehensive review of glyc... 20
Agreement between different eG... 19
Investigation of cytokine chan... 19
Expressions of vascular endoth... 17
Role of Th1/Th2 imbalance medi... 16
Small patients, big challenges... 9
The frequency of EGFR gene mut... 8

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 31(3)/2023 DOI:10.2478/rrlm-2023-0019
XML
TXT

Research article

Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest

Delia C Popa, Horia M. Sandu, Raluca Suciu, Valeria G. Ţica, Andreea Şerbănică, Ionut Şerbănică, Cristina Jercan, Daniel Coriu, Alina Tanase, Anca Coliţă

Correspondence should be addressed to: Valeria G. Ţica, Raluca Suciu

Abstract:

Introduction: Over the past few years, the introduction of chimeric antigen receptor (CAR) T-cell therapy by the FDA has shown remarkable success in treating various hematologic malignancies. However, the limited response and resistance observed in some patients have hindered its broader application. Methods: At Fundeni Clinical Institute, we implemented the use of Tisagenlecleucel, a second-generation CAR T cell therapy, in April 2022. This therapy targets CD19, an antigen expressed in all B lineage cells. To assess the cellular kinetics of CAR T cell-treated patients and conduct further research, we developed an 8-color/10-parameter flow cytometry tube. This tube utilizes a biotinylated CD19 CAR Detection Reagent with high sensitivity and specificity for CD19-targeted CARs, enabling us to effectively separate CAR T cells from normal T cells. Results: Through immunophenotyping, we successfully identified circulating CAR T cells and distinguished various subtypes of immune cells in the peripheral blood of infused patients. Furthermore, we validated the accuracy of our flow cytometry panel for monitoring the progress of CAR T cell therapy. Conclusions: This paper highlights the implementation of our flow cytometry monitoring panel for CAR T cells following Tisagenlecleucel therapy at Fundeni Clinical Institute. Our practical solution allows us to identify CAR T cells, assess B cell presence, and characterize different T cell subtypes in our patients. This standardized approach enhances our understanding and monitoring of CAR T cell therapy, leading to improved patient care and outcomes.

Keywords: CAR T, Tisagenlecleucel, cellular therapy, flow cytometry

Received: 27.4.2023
Accepted: 28.6.2023
Published: 7.7.2023

 
  PDF Download full text PDF
(1614 KB)
     
 
How to cite
Popa DC, Sandu HM, Suciu R, Ţica VG, Şerbănică A, Şerbănică I, et al. Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest. Rev Romana Med Lab. 2023;31(3):175-84. DOI:10.2478/rrlm-2023-0019